Dr. Sue Currie serves as Chief Operating Officer of Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies. Virion’s pipeline includes a novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure. She has 20+ years of strategic, operational, and scientific leadership experience in clinical research and development programs, from discovery to post-launch, focusing on cancers and infectious diseases. Before joining Virion, Dr. Currie was Vice President, Head of Medical Affairs, at Nektar Therapeutics, where she held global executive and corporate leadership roles within the company and was a core member of the Research and Development senior leadership team. Dr. Currie has biotech leadership experience and has been instrumental in the study design and strategies for clinical programs, as well as the scientific analyses and dissemination of these data in various forums. Before Nektar, Dr. Currie held senior clinical, medical and research positions at Health Interactions, as well as at Genentech/Roche in the immuno-oncology arena.
She has authored numerous pivotal scientific publications in immuno-oncology and infectious diseases, including human immunodeficiency virus, hepatitis virus, and coinfection treatment guidelines. Additionally, she has been a leader in external and internal health educational global and national programs and clinical resources for healthcare providers and other stakeholders in hepatitis and liver diseases and oncology.
Dr. Currie received her BA&S (Hon.) from the University of Saskatchewan, Saskatoon, Canada, her M.A. from the University of Phoenix, Vancouver, Canada, and her Ph.D. from the University of San Francisco. Sue brings a patient-centric focus to her leadership, from her unique experiences, not only within biotechnology, but from her work within the Veterans Health Administration, academic, correctional health, and community care settings, which includes her current work on a functional cure for patients with chronic HBV.
